Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product ...

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The FDA is alerting veterinarians about reports of health problems in dogs, including hundreds of deaths, tied to a drug for ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

Although these results are informative, they could not be used to gain FDA approval for Trikafta to treat additional ...

The US FDA has approved Vtama 1% cream for the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 ...

Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...